Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
Uncovering the mechanisms by which inflammasomes drive aberrant inflammation in humans to identify new therapeutic targets for autoinflammatory diseases and sepsis.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
